AF
ORMP icon

Aquamarine Financial’s Oramed Pharmaceuticals ORMP Stock Holding History

Aquamarine Financial’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.18M Buy
2,112,312
+139,255
+7% +$472K 0.53% 11
2025
Q4 		$5.62M Hold
1,973,057
– – 0.46% 9
2025
Q3 		$5.21M Buy
+1,973,057
New +$4.36M 0.53% 8

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
GIA
Gem Investment Advisors Teaneck, New Jersey $102M AUM
M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $5.76B AUM 24.57% 1-Year Est. Return

Aquamarine Financial's ORMP Position: Q1 2026 in Review

Aquamarine Financial increased its Oramed Pharmaceuticals (ORMP) stake by 7.1% in Q1 2026, buying an estimated $472K and bringing the position to 2,112,312 shares worth $7.18M. The position accounts for 0.53% of the portfolio, ranked #11.

Aquamarine Financial first reported a position in ORMP in Q3 2025 and has held it in 3 quarters since. 64 funds tracked by Wall St. Rank hold ORMP as of Q1 2026.

  • Aquamarine Financial held 2,112,312 shares of Oramed Pharmaceuticals worth $7.18M as of Q1 2026.
  • Aquamarine Financial bought 139,255 Oramed Pharmaceuticals shares in Q1 2026, an estimated $472K.
  • Oramed Pharmaceuticals made up 0.53% of Aquamarine Financial's portfolio in Q1 2026, its #11 holding.
  • Aquamarine Financial first reported a position in Oramed Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 64 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q1 2026.

Based on Aquamarine Financial's 13F filing for Q1 2026, filed 15 May 2026.